The U.S. Food and Drug Administration has granted marketing approval for a new blood test designed to detect pathological signs of Alzheimer’s disease in adult patients experiencing cognitive symptoms, according to federal regulators and test developer Fujireio Diagnostics. The test, marketed as the Lumipulse G β-Amyloid 1-42/1-40 plasma assay, measures specific amyloid-beta proteins in the blood to help clinicians evaluate individuals evaluated for memory decline or other forms of cognitive impairment.
According to the FDA announcement, the in vitro diagnostic tool provides an alternative to more invasive and costly diagnostic procedures, such as positron emission tomography (PET) scans or lumbar punctures, which analyze cerebrospinal fluid. The assay identifies the ratio of amyloid-beta 42 to amyloid-beta 40 peptides in human plasma. A lower ratio typically correlates with a higher likelihood of amyloid-beta plaque accumulation in the brain, a hallmark neuropathological feature of Alzheimer’s disease.
Clinical Impact and Diagnostic Utility
Physicians evaluating patients aged 55 and older presenting with cognitive decline can use the plasma test results to determine whether further specialized diagnostic workups are necessary. According to data reviewed by the agency during its premarket review pathway, the blood test demonstrates high concordance with amyloid PET scan results, which have historically served as a primary non-invasive benchmark for confirming amyloid pathology. Fujireio Diagnostics noted that the assay is intended to be ordered by healthcare professionals as part of a comprehensive neurological evaluation.
Early and accurate detection of Alzheimer’s pathology carries heightened clinical significance following the regulatory approval of disease-modifying therapies, such as lecanemab and donanemab. These monoclonal antibodies target amyloid-beta plaques in the early stages of cognitive impairment. Medical experts emphasize that blood-based biomarkers streamline the referral process for specialized care and therapeutic eligibility, reducing wait times associated with imaging appointments.
Regulatory Evaluation and Safety Data
The FDA evaluated the Lumipulse G assay through the De Novo premarket review pathway, a regulatory mechanism for novel, low-to-moderate-risk devices. The agency assessed clinical performance data from validation studies that analyzed blood samples from patients with documented cognitive impairment. The studies measured the test’s ability to correctly identify the presence or absence of brain amyloid accumulation as confirmed by reference standards.
Federal regulators noted several important limitations for the assay. The test does not serve as a standalone diagnostic tool for Alzheimer’s disease. Instead, results must be interpreted alongside patient history, neurological examinations, and other diagnostic tests. False-positive and false-negative results can occur, meaning patients with a positive blood test still require confirmatory clinical assessments before doctors establish a formal diagnosis or initiate treatment plans.
Availability and Future Adoption
Fujireio Diagnostics indicated that the assay runs on existing automated laboratory instruments already utilized in many hospital and commercial reference labs, which could facilitate broader clinical adoption. Healthcare systems are currently preparing protocols to integrate plasma biomarker testing into routine memory clinic workflows. Coverage determinations by Medicare and private insurers regarding blood-based Alzheimer’s tests remain a key factor influencing how rapidly clinics adopt the technology for everyday patient care.